pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

General characteristics of participants in drug offender education programs

Characteristics Total population (n=540) Stimulants (n=300) Cannabis (n=139) Opioids and sedatives (n=34) Others (n=29) p-Value
Type of Education Program, N (%)
Deferred Prosecution 233 (43.1%) 104 (34.7%) 66 (47.5%) 15 (44.1%) 21 (72.4%) <0.001
Probation 307(56.9%) 196 (65.3%) 73 (52.5%) 19 (55.9%) 8 (27.6%)
Sex, N (%)
Male 376 (70.8) 211 (71.3%) 119 (86.2%) 9 (26.5%) 11 (39.3%) <0.001
Female 155 (29.2) 85 (28.7%) 19 (13.8) 25 (73.5%) 17 (60.7%)
Age, N (%)
<30 years 176 (33.4%) 83 (28.0%) 53 (39.0%) 12 (37.5%) 18 (64.3%) <0.001
30-39 years 146 (27.7%) 81 (27.4%) 44 (32.4%) 7 (21.9%) 3 (10.7%)
≥40 years 205 (38.0%) 132 (44.6%) 39 (28.7%) 13 (40.6%) 7 (25.0%)
Duration of drug use, N (%)
<2 years 298 (60.6%) 176 (61.1%) 85 (64.4%) 10 (33.3%) 17 (58.6%) 0.017
≥2 years 194 (39.4%) 112 (38.9%) 47 (35.6%) 20 (66.7%) 12 (41.4%)
Education, N (%)
Incomplete compulsory education 119 (22.2%) 51 (17.1%) 17 (12.4%) 5 (14.7%) 7 (24.1%) 0.384
Complete compulsory education 417 (77.8%) 247 (82.9%) 120 (87.6%) 29 (85.3%) 22 (75.9%)
Annual income (won), N (%)
<30,000,000 239 (44.7%) 136 (49.3%) 45 (33.8%) 19 (61.3%) 20 (80.0%) <0.001
30,000,000~60,000,000 184 (36.7%) 96 (34.8%) 62 (46.6%) 11 (35.5%) 1 (4.0%)
>60,000,000 78 (15.6%) 44 (15.9%) 26 (19.5%) 1 (3.2%) 4 (16.0%)
Previous treatment experience, N (%)
Treatment-naive 389 (73.1%) 196 (65.6%) 112 (83.0%) 26 (76.5%) 20 (76.9%) 0.002
Treatment-experienced 143 (26.9%) 103 (34.4%) 23 (17.0%) 8 (23.5%) 6 (23.1%)
Employment, N (%)
Unemployed 137 (25.4%) 71 (24.3%) 25 (18.2%) 13 (40.6%) 14 (48.3%) 0.001
Employed 391 (72.4%) 221 (75.7%) 112 (81.8%) 19 (59.4%) 15 (51.7%)
Marital status, N (%)
Unmarried 417 (77.8%) 227 (75.7%) 109 (79.6%) 31 (91.2%) 23 (85.2%) 0.143
Married 119 (22.2%) 73 (24.3%) 28 (20.4%) 3 (8.8%) 4 (14.8%)
Social support measured by MOS-SSS, N (%)
Poor (0-19 score) 253 (46.9%) 146 (48.7%) 62 (44.6%) 18 (52.9%) 18 (62.1%) 0.354
Good (≥20 score) 287 (53.1%) 154 (51.3%) 77 (55.4%) 16 (47.1%) 11 (37.9%)
Mental health, N (%)
Good (0-4 score) 291 (53.9%) 148 (49.3%) 91 (65.5%) 9 (26.5%) 12 (41.4%) <0.001
Poor (≥5 scores) 249 (46.1%) 152 (50.7%) 48 (34.5%) 25 (73.5%) 17 (58.6%)
Depression measured by PHQ-9, N (%)
No (0~4 score) 328 (60.7%) 181 (60.3%) 95 (68.3%) 10 (29.4%) 13 (44.8%) <0.001
Yes (≥5 scores) 212 (39.3%) 119 (39.7%) 44 (31.7%) 24 (70.6%) 16 (55.2%)
MLQ, N (%)
Bad (0-46 score) 221 (41.5%) 121 (40.6%) 52 (38.0%) 17 (51.5%) 13 (48.1%) 0.454
Good (≥47 score) 312 (58.5%) 177 (59.4%) 85 (62.0%) 16 (48.5%) 14 (51.9%)
Drug Abuse Screening Test-10, N (%)
Negative (0-1 score) 121 (22.4%) 45 (15.0%) 36 (25.9%) 7 (20.6%) 7 (24.1%) 0.050
Positive (≥2 score) 419 (77.6%) 255 (85.0%) 103 (74.1%) 27 (79.4%) 22 (75.9%)

MOS-SSS; Medical outcomes study social support survey, PHQ, Patient Health Questionnaire; MLQ, Meaning in Life Questionnaire; Analysis is chi-square test.

Korean J Clin Pharm 2024;34:222-31 https://doi.org/10.24304/kjcp.2024.34.4.222
© 2024 Korean J Clin Pharm